Mode
Text Size
Log in / Sign up

Adjunctive Yuehua Decoction linked to improved quality of life in multidrug-resistant TB patientsA Traditional Herb May Ease the Burden of Drug-Resistant TB

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider adjunctive Yuehua Decoction may improve quality of life in MDR-TB, but evidence is preliminary and observational.

This was a prospective cohort study of 71 adults with microbiologically confirmed multidrug-resistant tuberculosis. Participants received either adjunctive Yuehua Decoction with standard MDR-TB chemotherapy (n=32) or standard chemotherapy alone (n=39) for 6 months.

The primary outcome was health-related quality of life at 6 months, assessed using the St. George’s Respiratory Questionnaire (SGRQ). Adjunctive Yuehua Decoction was associated with greater improvement after adjustment for baseline imbalance (adjusted β = –3.00; 95% CI: –3.87 to –2.12; P < 0.001). Sputum culture conversion and overall treatment success were comparable between groups, with no significant difference reported.

Safety data showed skin reactions occurred in 15.6% of the Yuehua group versus 35.9% in the control group (P = 0.038). No increase in serious adverse events was observed. Discontinuations and overall tolerability were not reported.

Key limitations include the non-randomized design, significantly higher baseline SGRQ scores in the Yuehua group, and preliminary findings that need confirmation in larger randomized controlled trials. The association reported is not causation.

Practice relevance is restrained: findings support Yuehua Decoction as a potential host-directed adjunct for improving HRQoL in MDR-TB patients, but confirmation in larger RCTs is needed.

Imagine fighting a lung infection that takes months to treat, with medicines that make you feel sick. Now, imagine a simple herbal tea that could help you feel better during that fight. That is the question a new study is exploring.

Multidrug-resistant tuberculosis, or MDR-TB, is a serious form of TB that does not respond to standard drugs. The treatment is long—often 18 months or more—and involves powerful antibiotics that can cause severe side effects. These side effects can harm a patient’s quality of life, making the treatment hard to finish.

The Heavy Toll of Resistant TB

MDR-TB affects thousands of people worldwide each year. It is not just a lung disease; it is a life disruptor. Patients often feel exhausted, depressed, and physically weak. The standard treatment involves a cocktail of drugs that can cause nausea, joint pain, and skin rashes.

Current treatments focus only on killing the bacteria. But what about the person taking the medicine? Their quality of life is often overlooked. This is where researchers are looking for new approaches. They are exploring "host-directed therapies"—treatments that support the patient's own body, not just the germ.

A New Look at an Old Remedy

For centuries, Traditional Chinese Medicine (TCM) has used herbal formulas to treat various illnesses. Yuehua Decoction is one such formula. It combines several herbs believed to boost the immune system and reduce inflammation.

But does it actually help people with modern, drug-resistant TB? Until now, there has been little scientific proof. This new study from Frontiers in Medicine is one of the first to test it in a real-world clinical setting.

The study did not use the gold-standard random assignment. Instead, patients chose their treatment path. Some took standard TB drugs alone. Others took the standard drugs plus Yuehua Decoction. This is a key point we will come back to.

Think of the immune system as a security team for your body. In TB, the bacteria are the intruders. Standard drugs are the police, sent to arrest the intruders. But the fight can get messy, and the "crime scene" (your lungs) gets damaged.

Yuehua Decoction may act like a support crew. It might help calm the inflammation—the swelling and damage—that the fight causes. By reducing this collateral damage, the patient might simply feel better, even if the bacteria are still being cleared by the standard drugs.

The Study Snapshot

Researchers enrolled 71 adults with confirmed MDR-TB. About half took standard chemotherapy alone. The other half took chemotherapy plus Yuehua Decoction. They followed everyone for six months. The main goal was to measure quality of life using a standard breathing and health survey.

After six months, the group taking Yuehua Decoction reported a noticeable improvement in their quality of life. Their scores on the health survey were better than the group taking standard drugs alone.

The difference was small but consistent. It was just below the threshold doctors consider a "clinically important" change. However, the result was precise, suggesting it is not just random chance.

Here is the most practical finding: fewer side effects. Patients in the Yuehua group had significantly fewer skin reactions—a common and bothersome side effect of TB drugs. About 16% of them had skin issues, compared to 36% in the standard treatment group.

Importantly, the herb did not interfere with the TB drugs. Sputum culture conversion—the measure of the bacteria being cleared—was similar between the two groups.

But there’s a catch.

This was not a randomized study. Patients chose their treatment. This means the two groups might have been different from the start, even after the researchers adjusted their math. For example, the Yuehua group started with slightly worse quality-of-life scores. This makes the improvement look bigger than it might be. We cannot be 100% sure the herb caused the improvement.

Researchers see this as a promising first step. It shows that a host-directed therapy like Yuehua Decoction is safe and may help patients tolerate their treatment better. The focus on quality of life is a crucial shift in how we treat chronic infections. However, experts agree that this is preliminary. A larger, randomized trial is the next essential step to confirm these findings.

If you or a loved one has MDR-TB, this is not a treatment you can ask for tomorrow. Yuehua Decoction is not a standard part of care outside of China, and it is not a replacement for prescribed antibiotics. The study suggests it might be a helpful addition to standard care, but only under a doctor's supervision. Do not stop your current treatment or try this on your own.

This does not mean this treatment is available yet.

The study was small and non-randomized. These are significant limitations. The results are a signal, not a conclusion. We need more research to know if this works for everyone and to rule out any hidden risks.

The next step is a larger, randomized controlled trial. This is the type of study that can give us stronger answers. Researchers will need to test Yuehua Decoction in a more diverse group of patients over a longer period. If those trials are successful, it could one day become a standard supportive therapy for MDR-TB, helping patients not just survive, but feel better while they heal.

Study Details

Study typeRct
EvidenceLevel 2
PublishedApr 2026
View Original Abstract ↓
BackgroundMultidrug-resistant tuberculosis (MDR-TB) remains a major global health challenge, and prolonged chemotherapy often leads to substantial symptom burden and impaired health-related quality of life (HRQoL). Host-directed adjunctive therapies, including Traditional Chinese Medicine, have received growing interest; however, prospective clinical evidence on Yuehua Decoction remains limited. This study evaluated whether adjunctive Yuehua Decoction improves HRQoL and safety among patients receiving standardized MDR-TB treatment.MethodsWe conducted a prospective, non-randomized cohort study enrolling adults with microbiologically confirmed MDR-TB. Patients received either standard MDR-TB chemotherapy alone (control group) or in combination with Yuehua Decoction (Yuehua group) based on treatment preference. The primary outcome was HRQoL at 6 months, assessed using the St. George’s Respiratory Questionnaire (SGRQ). Between-group differences were analyzed using multivariable linear regression adjusting for baseline SGRQ and other clinically relevant covariates. Secondary outcomes included sputum culture conversion and treatment-related adverse events.ResultsSeventy-one patients were included (Yuehua group, n = 32; control group, n = 39). Although demographic characteristics were similar, baseline SGRQ scores were significantly higher in the Yuehua group (P = 0.007). After adjustment for this imbalance, adjunctive Yuehua Decoction was associated with greater improvement in SGRQ total score at 6 months (adjusted β = –3.00; 95% CI: –3.87 to –2.12; P < 0.001). The between-group difference was slightly below the conventional minimal clinically important difference (4 points), but the direction and precision of the estimate suggest potential clinical relevance. Rates of sputum culture conversion and overall treatment success were comparable between groups. A significantly lower incidence of skin reactions was observed in the Yuehua group (15.6% vs. 35.9%, P = 0.038), with no increase in serious adverse events.ConclusionIn this preliminary prospective cohort, adjunctive Yuehua Decoction was associated with improved HRQoL without increasing treatment-related toxicity among patients undergoing MDR-TB chemotherapy. These findings support Yuehua Decoction as a potential host-directed adjunct, but confirmation in larger randomized controlled trials is needed.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.